Lerner Research Institute News
Read about the latest advances from Lerner Research Institute scientists, including new findings, grant awards, innovations and collaborations.
The Molecular Medicine PhD Program offers a track for Cleveland Clinic residents/fellows in accredited training programs who wish to pursue a PhD in laboratory-based research. Known as PRISM (Physician Researchers Innovating in Science and Medicine), the program is completely housed and administered at Cleveland Clinic. This year the program welcomed three new residents/fellows:
- Takae Brewer (left): Takae received a BS in biology from International Christian University (Japan), a BS in medical technology from Old Dominion University and a MD from Eastern Virginia Medical School. She completed her internal medicine residency at University of Florida and hematology/oncology fellowship at University of Kansas. Since 2018, she has been an Ambrose Monell Cancer Genomic Medicine Clinical Fellow under the mentorship of Dr. Charis Eng in Lerner’s Genomic Medicine Institute. Her research interests include cancer biology and genetics, as well as novel cancer therapeutics.
- Haytham Elgharably (middle): Haytham received Bachelor of Medicine and Bachelor of Surgery degrees, as well as a Master of Surgery degree from Zagazig University (Egypt). Since 2013, he has been a resident in the Integrated Thoracic Surgery Department at Cleveland Clinic. His research interests include ischemia-reperfusion injury of human lungs after transplantation, cardiovascular biofilm infection and right-sided heart failure.
- Caleb Seavey (right): Caleb received a BA in biology and a MD from George Washington University. During his time at the National Institutes of Health, his research focused on cardiac xenotransplantation immunology. Since 2017, he has been a general surgery resident in the Digestive Disease and Surgical Institute at Cleveland Clinic. His clinical interest is in surgical oncology, and his work in Dr. Rubin’s lab in the Department of Cancer Biology relates to preclinical models of breast cancer and breast tumorigenesis.